Portal de Periódicos da CAPES

Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

2022; Wiley; Volume: 37; Issue: 1 Linguagem: Inglês

10.1111/jdv.18563

1468-3083

Cristina Muniesa Montserrat, Fernando Gallardo, I. García‐Doval, M. Teresa Estrach, Andrea Combalía, M. Morillo-Andújar, Fátima de la Cruz-Vicente, Salma Machán, Cristina Moya‐Martínez, Roger Rovira, Blanca Sánchez‐González, Elvira Acebo, Elena Amutio, Yeray Peñate, Maria del Carmen Losada‐Castillo, M.P. García-Muret, Helena Iznardo, Concepción Román‐Curto, Javier Cañueto, Ricardo Fernández‐de‐Misa, Ángeles Flórez, Rosa María Izu, Ignacio Torres‐Navarro, Ana Zayas, Gema Pérez‐Paredes, M. Blanes, Juan Ignacio Yanguas, A. Pérez‐Ferriols, Marta Callejas‐Charavia, Pablo L. Ortiz‐Romero, Amalia Pérez‐Gil, Lucía Prieto‐Torres, Eva González‐Barca, Octavio Servitje,

Nail Diseases and Treatments

Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.To evaluate the response and tolerance of BV in a cohort of patients with CTCL.We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.